Cardiogenic Shock
Cyrus Vahdatpour, MD; David Collins, MD; Sheldon Goldberg, MD, FACC

Cardiogenic shock (CS) is a common cause of mortality, and management remains challenging despite advances in therapeutic options. CS is caused by severe impairment of myocardial performance that results in diminished cardiac output, end-organ hypoperfusion, and hypoxia. Clinically this presents as hypotension refractory to volume resuscitation with features of end-organ hypoperfusion requiring pharmacological or mechanical intervention. Acute myocardial infarction (MI) accounts for 81% of patient presentations in CS.[2] Contemporary trials and guidelines (Table 1) outline clinical criteria for defining CS and are limited by lack of uniformity. The SHOCK (Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock) and intra-aortic balloon pump (IABP)-SHOCK II trials used systolic blood pressure (SBP) measurements of <90 mm Hg for ≥30 minutes or use of pharmacological and/or mechanical support to maintain an SBP ≥90 mm Hg.[1,3,4] Evidence of end-organ hypoperfusion varied between the trials but typically included urine output of <30 mL/h, cool extremities, altered mental status, and/or serum lactate >2.0 mmol/L.[1,3,4] The SHOCK Trial included cardiac index (CI) of ≤2.2 L/min per m² and a pulmonary capillary wedge pressure (PCWP) of ≥15 mm Hg.[3] An SBP <90 mm Hg that is refractory to fluid resuscitation with clinical and laboratory evidence of end-organ dysfunction, in the setting of suspected cardiac dysfunction, is essential to the definition of CS. However, CS is a continuum that extends from pre-shock to refractory shock states, which influence the timely considerations of various interventions.[6] Acknowledging this continuum in future trials would likely facilitate the unification of clinical and hemodynamic criteria in defining CS.

Epidemiology
CS complicates 5% to 10% of cases of acute MI and is the leading cause of death after MI.[1,9] ST-segment–elevation myocardial infarction (STEMI) is associated with a 2-fold increased risk of development of CS compared with non–ST-segment–elevation myocardial infarction (NSTEMI). Patients with NSTEMI-associated CS are less likely to undergo early cardiac catheterization, delaying PCI and/or coronary artery bypass graft and increasing the risk of mortality compared with patients with STEMI-associated CS.[10] Higher incidences of CS are observed in women, Asian/Pacific Islanders, and patients aged >75 years.[9] The incidence of CS has increased in recent years, while the reason for increasing incidence is unclear, improved diagnosis and better access to care are both likely contributory.[9] While the in-hospital mortality has improved,[1] the 6– to 12-month mortality in cardiogenic shock has remained unchanged at ≈50% over the past 2 decades.[3,4,11]

Survivors of MI-associated CS have an 18.6% risk of 30-day readmission after discharge, with a median time of 10 days. The risk of readmission is slightly lower among patients with STEMI versus NSTEMI. The most common causes of readmission are congestive heart failure and new myocardial infarction. Female sex, low socioeconomic status, mechanical circulatory support (MCS) device placement, atrial fibrillation, and ventricular tachycardia are predictors of readmission.[12]

Pathophysiology
The primary insult is a reduction in myocardial contractility resulting in diminished cardiac output, hypotension, systemic vasoconstriction, and cardiac ischemia.[1] The hallmark is peripheral vasoconstriction and vital end-organ damage, which stems from ineffective stroke volume and insufficient circulatory compensation.[1,13] Compensatory peripheral vasoconstriction may initially improve coronary and peripheral perfusion, however it contributes to increased cardiac afterload that overburdens damaged myocardium.[1,13] This results in diminished oxygenated blood flow to peripheral tissue and, ultimately, the heart.
Table 1. Clinical Features of CS as Defined in Contemporary Trials and Guidelines

| Clinical Trial/Guideline | CS Criteria |
|-------------------------|-------------|
| SHOCK Trial (1999)³     | • SBP <90 mm Hg for >30 min or vasopressor support to maintain SBP >90 mm Hg  
  • Evidence of end-organ damage (UO <30 mL/h or cool extremities)  
  • Hemodynamic criteria: CI <2.2 and PCWP >15 mm Hg |
| IABP-SOAP II (2012)⁴    | • MAP <70 mm Hg or SBP <100 mm Hg despite adequate fluid resuscitation  
  (at least 1 L of crystalloids or 500 mL of colloids)  
  • Evidence of end-organ damage (AMS, mottled skin, UO <0.5 mL/kg for 1 h, or serum lactate >2 mmol/L) |
| EHS-PCI (2012)⁵         | • SBP <90 mm Hg for 30 min or inotropes use to maintain SBP >90 mm Hg  
  • Evidence of end-organ damage and increased filling pressures |
| ESC-HF Guidelines (2016)⁶| • SBP <90 mm Hg with appropriate fluid resuscitation with clinical and laboratory evidence of end-organ damage  
  • Clinical: cold extremities, oliguria, AMS, narrow pulse pressure. Laboratory: metabolic acidosis, elevated serum lactate, elevated serum creatinine |
| KAMIR-NIH (2018)⁷       | • SBP <90 mm Hg for >30 min or supportive intervention to maintain SBP >90 mm Hg  
  • Evidence of end-organ damage (AMS, UO <30 mL/h, or cool extremities) |

AMS indicates altered mental status; CI, cardiac index; EHS PCI, Euro Heart Survey Percutaneous Coronary Intervention Registry; ESC HF, European Society of Cardiology Heart Failure; IABP-SOAP II, intra-aortic balloon pump in cardiogenic shock II; KAMIR-NIH, Korean Acute Myocardial Infarction Registry-National Institutes of Health; MAP, mean arterial pressure; PCWP, pulmonary capillary wedge pressure; SBP, systolic blood pressure; SHOCK, Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock; UO, urine output.

Systemic inflammation causes pathological vasodilation, releasing nitric oxide synthase and peroxynitrite, which have cardiotoxic inotropic effects.¹,¹³ Interleukins and tumor necrosis factor alpha (TNF-α) are additional systemic inflammatory mediators that result in vasodilation and contribute to mortality in patients with CS.¹,¹⁴

Under normal physiological stresses, the right ventricular stroke volume and the left ventricular stroke volume are equal. Right ventricular failure (RVF) occurs when the ventricular diastolic and/or systolic pressures are insufficiently compensated by normal myocardial adaptive processes to provide appropriate stroke volumes.¹⁵ Inadequate forward blood flow in a compromised right ventricle (RV) accounts for end-organ perfusion deficits in conjunction with increased venous pressures.¹⁵ The RV is less adaptive to pressure afterload and more tolerant of volume overload than the left ventricle (LV) and this explains the inability of the right ventricle to tolerate severely elevated pulmonary artery pressures.¹⁵ As RVF results in RV dilation, the interventricular septum is displaced into the left ventricular space, compromising LV diastolic filling and further exacerbating systemic hypoperfusion.¹⁵,¹⁶

Clinical Presentation and Physical Examination

In the setting of CS, classic ACS symptoms and signs are combined with altered mental status, hypotension, arrhythmia, diminished pulses, dyspnea, peripheral edema, jugular venous distention, and orthopnea (Figure 1). These features reflect an infarction involving >40% of the left ventricle,¹⁷ and can occur in the setting of an acute infarct superimposed on an old MI or a new massive MI.

Patients with CS most commonly present with cool extremities and signs of pulmonary congestion. This presentation is termed “cold and wet” and reflects a reduced cardiac index (CI), increased systemic vascular resistance, and increased PCWP. Patients may also present euvoletic or “dry and cold”, which indicates a reduced CI, increased systemic vascular resistance, and normal PCWP. Euvolemic presentations were more likely to have previous MI or chronic kidney disease in comparison with those with classic “cold and wet” features.¹⁸

An under-recognized presentation of CS is the “wet and warm” subtype. This represents a systemic inflammatory response syndrome reaction in conjunction with an MI and is associated with a higher incidence of sepsis and mortality.¹³,¹⁹–²¹ These patients have a reduced CI, low-to-normal systemic vascular resistance, and an elevated PCWP. Systemic inflammatory response syndrome should be suspected by the presence of fever, an elevated white cell count, and low systemic vascular resistance. Nineteen percent of patients had suspected sepsis in the SHOCK trial, with higher risk in younger patients and those with low systemic vascular resistance.²¹ ACS-associated CS patients with culture-positive sepsis have 2 times the risk of mortality.²¹ Systemic inflammatory response syndrome is prevalent on admission in 25% of patients with STEMI. Tachycardia, tachypnea, and leukocytosis are independent risk factors for mortality.²⁰
Differential Diagnosis

Alternative diagnoses include other shock etiologies such as hypovolemic, distributive, and obstructive. Other types of shock may contribute to CS as either the main insult or in combination. Thorough medication reconciliation should be performed to discontinue agents that exacerbate hemodynamic dysfunction.

Initial Investigations

Cardiac catheterization is both the definitive diagnostic investigation and guides therapeutic intervention in CS complicating acute MI. Cardiac catheterization is typically preceded by several initial investigations and non-interventional management strategies. However, CS is a clinical diagnosis and no investigation should delay emergent cardiac catheterization.

ECG

The ECG should be ordered within 10 minutes of presentation. ECG findings in ACS are divided into 3 groups: ST-segment elevation, ST-segment depression, and non-ST-segment deviation. Early ECG changes of early coronary occlusion and transmural infarction includes hyperacute T waves, which tend to be short-lived and progress rapidly to ST-segment elevation. The presence of ST-segment elevation in ≥2 contiguous leads is an indication for urgent reperfusion. Transient ST-segment elevation, ST-segment depression, and/or T-wave inversions should raise clinical suspicion of ACS. These patients should be treated with aggressive medical therapy and be evaluated immediately for early coronary angiography. New guidelines suggest that left bundle branch block (LBBB) is no longer an indication for urgent catheterization. In the appropriate clinical context and in the presence of suggestive diagnostic evidence, urgent catheterization should still be considered. Pathologic Q waves are a reflection of total size of MI, rather than transmural extent, and their presence predicts a lower ejection fraction (EF) and a larger MI. In the absence of previously described changes and high clinical suspicion of ACS, true posterior wall myocardial infarction is suggested by the following: ST-segment depressions in the septal and anterior precordial leads (V1–V4), an R:S wave ratio >1 in V1-V2, ST-segment elevations in the posterior leads of a posterior ECG (V7–V9). If there is co-existing inferior wall myocardial infarction, there will be ST-segment elevations in the inferior leads (II, III, and aVF). A normal ECG is not necessarily reassuring as posterior and lateral walls are not fully represented on ECG and thus may not exclude ischemia. STEs confer a higher mortality risk in ACS complicated by CS. It has been suggested that patients have a similar 90-day prognosis if effective revascularization takes place, regardless of ST segment patterns. Other findings on (Figure 2) that are suggestive of ACS include sustained ventricular tachycardia, ventricular fibrillation, atrial fibrillation, new bundle branch block, or worsening of a symptomatic high-degree atrioventricular block.

Routine Initial Investigations

Complete blood counts and metabolic panels should be obtained every 12 to 24 hours as they offer valuable information about oxygenation, electrolyte status, and end-organ damage. Type 1 MI is caused by an acute atherothrombosis as result of plaque rupture or erosion. Frequent monitoring of troponins may reflect extent of injury that is time-dependent from the initial insult. In the setting of CS, as in STEMI, it is not recommended to wait for the presence of elevated cardiac enzymes before emergent catheterization. Troponins are
typically trended every 6 hours starting from initial clinical suspicion.

N-terminal pro-B-type natriuretic peptide (NT-proBNP) will be elevated during an acute decompensation of heart failure. In CS resulting from ACS, raised levels of natriuretic peptides are associated with increased mortality.\textsuperscript{31,32}

CS causes reduced oxygenation to peripheral tissues that results in lower pO2 levels and elevated pCO2 levels. Higher levels of lactic acid can be associated with increased mortality.\textsuperscript{33,34} Blood gas and lactic acid should be trended (eg, every 1–6 hours initially) to assess response to initial resuscitation.

Echocardiography may be beneficial, especially if there is clinical concern for an MI-related mechanical complication precipitating CS; however, it should not delay cardiac catheterization. Ultimately, patients presenting with acute RVF or LVF of suspected ischemic etiology should undergo immediate cardiac catheterization for the assessment of coronary anatomy, intracardiac pressures, valvular dysfunction, and structural impairments that often complicate ACS and contribute to CS.

**Stabilization and Resuscitation Strategy**

**Intravenous Fluids**

Fluid resuscitation strategy is a clinical challenge in the early management of CS as it is often difficult to assess and can
vary over time. In right-sided heart failure, right atrial pressures and pulmonary artery wedge pressures are poor predictors of fluid response.\textsuperscript{15,35} Echocardiography can assess right-sided heart volume status and rule out pericardial fluid collection.\textsuperscript{15} The definitive method of volume status assessment and adequacy of resuscitation is right heart catheterization, which should be performed in conjunction with coronary angiography. If hypovolemia is present, conservative boluses of crystalloids (250–500 mL) are reasonable while the patient is being stabilized for cardiac catheterization.

### Oxygenation and Ventilation

Continuous pulse oximetry should be used to monitor for respiratory compromise. Oxygen goals vary depending on patient comorbidities, but in the acute care setting blood oxygen saturations of $>90\%$ are acceptable.

When non-invasive forms of oxygenation and ventilation are inadequate, invasive ventilation is required. Low tidal volumes (5–7 mL/kg of ideal body weight) used in the management of acute respiratory distress syndrome are considered lung protective and decrease the incidence of RVF from 60\% to 25\% in this cohort of patients.\textsuperscript{36} Low tidal volumes optimize blood flow between the pulmonary and parenchymal vasculature. The decreased resistance in the pulmonary circuit lowers stress on the RV, compared with higher tidal volumes. Therefore, a low tidal volume strategy is recommended when mechanically ventilating patients in CS.

### Vasopressor Support

Vasopressors (Table 2) should be titrated to a mean arterial pressure with a typical goal of ≥65 mm Hg. Vasopressin has less pulmonary vasoconstriction than norepinephrine; and may be more beneficial as a first-line vasopressor in patients with CS with acute RVF.\textsuperscript{37} Pulmonary vasoactivity can be modified by inodulators, phosphodiesterase III inhibitors, or nitric oxide (Table 3). When using these agents invasive blood pressure monitoring is required as they can rapidly induce hypotension.

### Continuous Renal Replacement Therapy

Acute kidney injury occurs in 13\% to 28\% in patients with CS, and 20\% will require continuous renal replacement therapy.\textsuperscript{1,38,39} Continuous renal replacement therapy should be considered with stage 2 kidney injury as defined by elevated serum creatinine ($\geq2\times$ baseline) and urine output <0.5 mL/kg per hour for $\geq12$ hours; or when life-threatening changes in fluid, electrolyte, and acid-base balance precipitates the need for dialysis.\textsuperscript{40}

### Hemodynamic Monitoring

Goals of hemodynamic monitoring should be focused on hemodynamic modification to produce stable vital signs and adequate tissue perfusion. Continuous blood pressure monitoring with an arterial line, telemetry, continuous pulse oximetry, temperature, respiratory rate, and urinary output are rudimentary parameters to monitor.

Mixed venous oxygen saturation ($\text{SvO}_2$) is measured from a sample of blood drawn from the central venous system, ideally from the distal port of a pulmonary artery catheter. A low $\text{SvO}_2$ may indicate reduced CO, anemia, hypoxemia, or increased oxygen consumption.\textsuperscript{41} A reduced $\text{SvO}_2$ saturation is typically present in CS; however, this is also often the case in hypovolemic and obstructive shock. $\text{SvO}_2$ measurement can help assess response to therapy when measured frequently. During the early stages of hemodynamic monitoring, $\text{SvO}_2$ measurements should be drawn every 4 hours after central line placement.

Common structural complications of MI should be suspected by appearance of a new systolic murmur on clinical examination. Echocardiography can confirm early mechanical complications such as papillary muscle rupture, ventricular septal defect, and free wall rupture, which present most frequently within 24 hours of hospitalization.\textsuperscript{42,43} Right ventricular free wall hypertrophy indicates long term right-sided pressure elevation, while right ventricular dilation offers prognostic values.\textsuperscript{15,44} During the treatment phase, echocardiography and catheterization are used together to assess the hemodynamic response to intervention.

A pulmonary artery catheter (PAC) is typically placed during cardiac catheterization and can assist with identification of patients requiring mechanical circulatory support. It often remains in place thereafter for continuous hemodynamic monitoring—including precise measurements of fluid states, central venous oxygen saturation, response to therapy, and indicates the effectiveness of ventricular support. PACs offer therapeutic advantages via continuous monitoring of cardiac output during inotrope and pulmonary artery vasodilator titration.\textsuperscript{15,45} This intervention is helpful because patient response to mechanical circulatory support is dependent on several factors including volume status, intrinsic RV contractility, properties of the systemic and pulmonary vasculature, and the presence of valvular lesions.\textsuperscript{46} PACs can also aid the diagnosis of mechanical circulatory support device complications such as pump thrombosis.\textsuperscript{46} Pump thrombosis should be suspected in patients who exhibit clinical features of recurrent cardiogenic shock accompanied by sudden elevation of pulmonary artery or PCWP.

Despite its more precise measurements, PAC use does not confer a mortality benefit or reduce the length of intensive care unit or hospital stays. In fact its use in the critically ill has
been associated with increased mortality.\textsuperscript{47} Complications of PACs include pulmonary infarcts, cardiac arrhythmias such as heart block, infection, and balloon rupture. An LBBB, commonly seen in ACS, is a contraindication to a PAC without backup ventricular pacing because of the risk of precipitating a right bundle branch block (RBBB). In critically ill patients, a PAC is not always time effective and clinical decisions are frequently made in the absence of this investigation.

MCS Devices

While inotropic agents are used widely, mortality is higher with an increased number of prescribed inotropes/vasopressors.\textsuperscript{48,49} Furthermore, catecholamine therapy is associated with significant limitations including arrhythmias, increased myocardial oxygen consumption, and inadequate circulatory support.\textsuperscript{50} MCS devices (Table 4)\textsuperscript{11,51–53} offer significant advantages over vasopressor therapy including substantial cardiovascular support without increased risk of myocardial ischemia and possible decreased myocardial oxygen demand.\textsuperscript{54} Most importantly, there are registry data indicating that early MCS device use is associated with improved survival rates.\textsuperscript{49} Thus, early use of support devices is an important therapeutic intervention. Options for acute percutaneous MCS include the intra-aortic balloon pump (IABP), axial flow pumps (Impella LP 2.5, Impella CP), left atrial-to-femoral arterial ventricular assist devices (Tandem Heart) and venous-arterial extracorporeal membrane oxygenation (ECMO).

The left ventricular pressure-volume loop (PVL) illustrates the 4 phases of the cardiac cycle—(1) isovolumetric contraction, (2) ejection, (3) isovolumetric relaxation and (4) filling. In the absence of pathology the loop is trapezoidal with a rounded top, but the position and morphology of the loop depend on ventricular preload and afterload. Preload is the cardiac “wall stress”; it is the end-diastolic volume that results in the greatest average sarcomere stretch in the myocardium.

\begin{table}[h]
\centering
\caption{Summary of Systemic Vasopressors}
\begin{tabular}{|c|c|c|c|}
\hline
\textbf{Agents} & \textbf{Mechanism} & \textbf{Effect} & \textbf{Indications} & \textbf{Considerations} \\
\hline
Phenylinephrine & A1 agonist & Vasoconstriction & Various forms of shock & Caution in cardiac dysfunction as it increases afterload \\
Norepinephrine & A-C agonist & Inotropy, chronotropy, dromotropy, and vasoconstriction & Most common first line agent in shock & Most benefits demonstrated in septic shock \\
Epinephrine & A-C agonist & Inotropy, chronotropy, dromotropy, and vasoconstriction & Commonly used as second line agent or first line in anaphylactic shock & Surviving Sepsis Guidelines has most data for epinephrine as second line agent \\
Dopamine & Dose dependent A, B, and D agonism & Inotropy, dromotropy, chronotropy, and vasoconstriction (at highest doses) & Second line agent in most forms of shock & SOAP II trial demonstrated more incidence of tachyarrhythmias and increased mortality in CS patients when dopamine was used as first line \\
Vasopressin & V1 agonist & Vasoconstriction & Second line agent in most forms of shock & On or Off dosing, can cause hypotension \\
Dobutamine & B agonist & Inotropy and mild vasodilation & Commonly used in cardiogenic shock & May contribute to hypotension \\
Levosimendan & Myofilament Ca\textsuperscript{2+} sensitizer and K+ channel modifier & Ionotropy and inodilator & Used in acutely decompensated chronic heart failure & Minimal effect on myocardial oxygen consumption \\
\hline
\end{tabular}
\end{table}

\begin{table}[h]
\centering
\caption{Summary of Vasoactive Agents Within the Pulmonary Circuit}
\begin{tabular}{|c|c|c|c|}
\hline
\textbf{Agent} & \textbf{Mechanism} & \textbf{Route} & \textbf{Side Effects} \\
\hline
Nitric Oxide & ↑ cGMP & Inhaled & Blurred vision, confusion, sweating, malaise, headache, bleeding \\
Milrinone & Phosphodiesterase 3 inhibitor & Intravenous & Bleeding, hypotension, chest pain, tremors, bronchospasm, hypokalemia \\
Prostacyclin & ↑ cAMP, ↑ K, ↓ ET-1, and ↑ K+ & Inhaled or Intravenous & Bleeding, arrhythmias, diarrhea, edema, fevers, chills \\
Dobutamine & B agonist & Intravenous & Hypotension, tachyarrhythmia, headache, thrombocytopenia \\
\hline
\end{tabular}
\end{table}
Afterload is the pressure that the left ventricle contracts against and is determined by the hemodynamic characteristics of the vascular system. The PVL and normal LV mechanics provide a basis for understanding ventricular mechanical support devices (Figure 3). They also offer insight into myocardial oxygen consumption, which is related to the ventricular pressure-volume area.46

There are 3 circuit configurations for MCS devices—pumping from the (1) RA/central vein to a systemic artery, (2) LA to a systemic artery or (3) LV to a systemic artery. Peak flow rates of available devices range from 2.5 to 7 L/min.46

The IABP was introduced almost 5 decades ago and remains the most common support device used in CS. IABP is believed to decrease myocardial oxygen consumption, increase coronary artery perfusion, decrease afterload and modestly increase cardiac output (0.8—1 L/min).16 It is inserted via an 8Fr sheath in either the femoral or axillary artery.56

The IABP Shock II Trial included 600 patients with CS from acute MI receiving early revascularization and randomized them to IABP support or optimal medical therapy. The study showed no mortality benefit at 30 days.4 Follow-up at 6 and 12 months showed no reduction in all-cause mortality or improvement in quality of life assessments.57 These findings may be because of the fact that the IABP plays no role in myocardium salvage.57,58 This study has a number of limitations. IABP insertion occurred within 24 hours, both before and after PCI. This does not align with contemporary thinking that emphasizes early MCS. However, pre- or post-PCI IABP insertion showed no mortality difference. Additionally, the pursuit of culprit versus multivessel PCI was determined by the operator. Furthermore, 30 crossovers occurred (26 of these non-protocol) to the IABP group and these may represent sicker patients.

There are a number of LV-to-aorta devices, however those most commonly used in the setting of CS are the Impella devices. The Impella devices are axial flow pumps that are advanced from the common femoral artery and passed retrograde across the aortic valve into the LV and eject blood into the ascending aorta. The Impella 2.5 and Impella CP devices are percutaneously inserted and can maintain a cardiac output of 2.5 to 4 L/min. Impella RP is a right-sided device introduced via an 11Fr catheter that pumps blood from the inferior vena cava to the pulmonary artery and delivers a flow rate >4 L/min. The Impella 5.0 is a larger device that can achieve a cardiac output of 5 L/min, however, it requires a 22-Fr sheath, necessitating a surgical cutdown of the femoral artery. Continuous pumping of blood from the LV,
independent of the cardiac cycle, results in the loss of the normal isovolumic periods, transforming the PVL from its trapezoidal morphology to a triangular shape. In contrast to the IABP, the Impella acts independent of heart function and rhythm and as the pump flow rate increases it progressively unloads the LV (resulting in a leftward PVL shift), peak LV pressure decreases and there are decreases in pressure-volume area and myocardial oxygen consumption. Also, aortic pressure increases with escalating flow rate causing a widening dissociation between aortic pressure and peak LV pressure (“LV-Ao uncoupling”). This unloading also results in decreased LA and wedge pressures. Impella use is contraindicated in moderate-to-severe aortic valve disease, mechanical aortic valve and severe peripheral arterial disease. Analysis of the Shock Trial Registry showed that cardiac power output (CPO) is the strongest independent hemodynamic correlate of mortality in CS. CPO couples both pressure (mean arterial pressure) and flow (cardiac output) variables to derive a numerical value of cardiac pumping (CPO = mean arterial pressure × cardiac output / 451). Impella has demonstrated greater intra-procedural hemodynamic stability (smaller decrease in mean arterial pressure and CPO). Thus, given the importance of CPO in CS and the improved hemodynamics offered by Impella, it appears to be the most optimal therapy.

The Protect II Trial showed that, in patients with complex triple-vessel or left main stem disease and severely reduced LV function undergoing non-emergent PCI, Impella provided superior hemodynamic support compared with IABP as
measured by CPO. Notably, the incidence of major adverse events at 30 days was not statistically different between these 2 groups. However, at 90 days, Impella was associated with decreased major adverse events. It should be noted that Protect II did not, however, include patients with CS.

Other advantages of Impella over IABP includes that it acts independent of heart function, simultaneously unloads the left ventricle and supports arterial pressure, permits prolonged balloon inflations, multiple passes with atherectomy devices, and supports circulation during complex coronary interventional procedures.

Although there is some evidence that Impella use results in reduced peri- and post-procedural major adverse events in high-risk PCI, the theoretical benefit of Impella over IABP is not borne out in larger trials of mechanical circulatory support in CS that are focused on major outcomes.

The IMPRESS in Severe Shock (IMPella versus IABP Reduces mortality in STEMI patients treated with primary PCI in Severe cardiogenic shock) trial was a randomized comparison of Impella CP versus IABP in patients suffering acute MI with CS. The primary end point was 30-day mortality and the study found no significant difference in 30-day mortality (≈50% for both groups). A limitation of the study was the small sample size (n=48). Notably, it supported prior findings of increased bleeding risk with Impella. Overall, the study suggests that the clinical benefits of Impella may be more similar to IABP than expected.

The SHOCK, IABP-SHOCK II, and IMPRESS in Severe Shock trials all showed ≈50% mortality over 6 to 12 months, illustrating the constant mortality outcomes in CS over the past 2 decades despite the widespread use of MCS devices. Recent analysis of the cVAD (Catheter-based Ventricular Assist Device) Registry indicates that early MCS implantation in CS, before starting inotrope/vasopressor support and before PCI, is independently associated with improved survival rates in patients with CS because of acute MI. With this in mind, the Detroit Cardiogenic Shock Initiative proposed the use of standardized protocols with emphasis on early Impella insertion before PCI. The Detroit Cardiogenic Shock Initiative Pilot Study reported 76% survival to discharge with this approach and is expanding into a National Cardiogenic Shock Initiative.

The Tandem Heart is an LA-to-arterial MCS device. A cannula is passed into the femoral vein and an atrial septal puncture is performed to access oxygenated LA blood, which is aspirated and pumped into one or both femoral arteries. Since blood is withdrawn directly from the LA this unloads the LV, resulting in decreased PCWP and LVEDP. It improves peripheral tissue perfusion in spite of the mild increase in afterload caused by the pumping of blood back into the femoral arteries. Use of Tandem Heart is limited by its requirement of a specialized skillset that includes transseptal puncture and time from door-to-LV unloading.

Venous arterial-ECMO involves drainage of venous blood, passing it through an oxygenator and returning the oxygenated blood to systemic circulation using a centrifugal pump. It can be performed centrally by cannulation of the right atrium and aorta or peripherally with cannulation of the femoral artery and vein. Peripheral ECMO can reduce LV preload; however, this can cause increased ventricular wall tension due to retrograde flow from femoral artery cannulation and therefore requires closer monitoring than central ECMO. ECMO has a complex and variable hemodynamic response, which may be partially explained by the variability of secondary effects of ECMO on total peripheral resistance and left ventricular contractility. ECMO has been used in ≈13 000 patients and its rate of survival-to-discharge is 39% when used in cardiac support. The absence of large randomized controlled trials of ECMO in patients with CS consigns its use to refractory cases as a bridging therapy to LVAD or emergent heart transplantation.

Coronary Angiography

The most important investigation in patients diagnosed with CS is coronary angiography (Figure 2). It enables physicians to identify the precise location of the lesion that precipitated CS. On coronary angiography ≈15% patients are found to have significant left main lesions and >50% have triple-vessel disease. Mortality is associated with the culprit vessel-left main coronary artery (78.6%), saphenous vein graft (69.7%), circumflex coronary artery (42.4%), left anterior descending coronary artery (42.3%) and right coronary artery (37.4%). Additionally, mortality is inversely related to the Thrombolysis in Myocardial Infarction flow grade. After evaluation of coronary anatomy patients typically undergo primary percutaneous coronary intervention (PCI). In rare instances, and dependent on institutional resources, patients may proceed to coronary artery bypass graft surgery, hybrid coronary artery bypass graft/PCI or emergent cardiac transplantation.

PCI Strategy

Coronary reperfusion is an essential therapeutic intervention for patients with ACS complicated by CS. The SHOCK trial provided strong evidence supporting the use of PCI in cardiogenic shock. There were 302 patients diagnosed with acute MI complicated by CS who were randomized to emergency revascularization or medical stabilization. Overall mortality at 30 days was similar between the revascularization and medical therapy groups. However, at 6 months mortality rates were significantly lower in the revascularization cohort (50.3%) in comparison with the medical therapy group (63.1%). The marked mortality benefit in successful
versus unsuccessful PCI was also clearly demonstrated, 35% versus 80% respectfully. Subgroup analysis of the SHOCK trial demonstrated a non-significant trend towards increased 30-day mortality in elderly patients receiving early revascularization versus initial medical stabilization. However, an early revascularization approach has subsequently been associated with lower short-term (54.5% versus 72.1%) and medium-term (60.4% versus 80.1%) mortality when compared with initial medical stabilization in this patient population. Of note, the SHOCK trial is now dated as only one-third of the revascularization cohort received intracoronary stents.

Complete revascularization, addressing both culprit and hemodynamically significant non-culprit lesions, has historically been the preferred strategy in patients with acute MI and CS and was recommended in recent guidelines; however, this paradigm has recently been challenged. The CULPRIT-SHOCK (Culprit Lesion Only PCI versus Multivessel PCI in Cardiogenic Shock) Trial randomized 706 patients with STEMI/NSTEMI and an identifiable culprit lesion to multivessel or culprit lesion-only PCI. The composite primary end point was death or renal failure requiring dialysis at 30 days. The trial demonstrated a 9.5% absolute risk reduction of the composite primary end point in the culprit lesion-only group (7.3% of which was attributable to an absolute risk reduction in all-cause mortality). Of note, the culprit-lesion only cohort had the option for staged revascularization of non-culprit lesions and almost 20% of patients underwent further staged or urgent PCI. Additionally, 75 patients crossed over from culprit lesion-only to multivessel PCI raising the possibility of including more complex and comorbid patients in the multivessel PCI group, thus overestimating the benefit of culprit lesion-only PCI. Also, greater dye loads in multivessel PCI may partially account for observed differences observed. Another limitation of the study was that low rates of MICS device use in the multivessel PCI group. One-year follow-up showed no mortality difference between the culprit lesion-only and multivessel PCI groups (50% versus 56.9%, respectively). The CULPRIT-SHOCK Trial contradicts widespread current practice and prior studies in non-shock patients (DANAMI-3-PRIMULTI, PRAMI, CULPRIT) that suggested that there may be a benefit from complete revascularization.

Data from the KAMIR-NIH (Korea Acute Myocardial Infarction-National Institutes of Health) Registry are at odds with the findings from the CULPRIT-SHOCK Trial. In this national multicenter prospective registry 659 patients with STEMI and CS who underwent PCI were studied. The risk of all-cause death at 1 year was significantly lower in the multivessel PCI group versus the culprit lesion-only group (21.3% versus 31.7%; \( P=0.001 \)). Furthermore, multivessel PCI was associated with reduced rates in the composite outcome of all-cause death, MI, and repeat revascularization (28.4% versus 42.6%; \( P<0.001 \)). Larger trials that stratify patients according to door-to-LV unloading time in tandem with randomization to culprit-lesion versus multivessel PCI are needed to resolve the discrepancy between the CULPRIT-SHOCK and KAMIR-NIH Registry findings.

Given the excellent long-term patency rates of left internal mammary grafts coupled with the advances in minimally invasive techniques and stent technology, hybrid coronary revascularization procedures are a promising treatment modality for CS patients with multivessel disease. Hybrid coronary revascularization refers to combined surgical bypass with PCI during the same procedure or within 60 days. Despite significant advances in infarct management, persistently high mortality rates have been observed in CS over the past 2 decades. However, available and emerging evidence indicates promising avenues for contemporary management. A new approach that emphasizes rapid LV unloading and prompt coronary revascularization may reduce mortality of this devastating complication of AMI.

Disclosures
None.

References
1. van Diepen S, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, Kilic A, Menon V, Ohman EM, Switzer NK, Thiele H, Washam JB, Cohen MG. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2017;136:e232–e262.
2. Harjola V-P, Lassus J, Sionis A, Keber L, Tarvainen T, Spinar J, Parisi J, Banaszewski M, Silva-Cardoso J, Carubelli V, Di Somma S, Tolpanen H, Zeymer U, Thiele H, Nieminen MS, Mebazaa A; for the CardShock study investigators and the GREAT network. Clinical picture and risk prediction of short-term mortality in cardiogenic shock: clinical picture and outcome of cardiogenic shock. Eur J Heart Fail. 2015;17:501–509.
3. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, Buller CE, Jacobs AK, Slater JN, Col J, McKinlay SM, Lejelmetl TH. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock? N Engl J Med. 1999;341:625–634.
4. Thiele H, Zeymer U, Neumann F-J, Ferenc M, Olbrich H-G, Hausleiter J, Richardt G, Hennersdorf M, Empen K, Fuermau G, Desch S, Eitel I, Hambrecht R, Fuhrmann J, Bohm M, Ebel H, Schneider S, Schuler G, Werdan K. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367:1257–1266.
5. Bauer T, Zeymer U, Hochadel M, Möllmann H, Weidinger F, Zahn R, Nef HM, Hamm CW, Marco J, Gitt AK. Use and outcomes of multivessel percutaneous coronary intervention in patients with acute myocardial infarction complicated by cardiogenic shock (from the EHS-PCI Registry). Am J Cardiol. 2012;109:941–946.
6. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola V-P, Jankowska EA, Jessup M, Linde C, Nikoyannopoulos P, Parissis J, Petersie B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–2200.
7. Lee JM, Rhee T-M, Hahn J-Y, Kim HK, Park J, Hwang D, Choi KH, Kim J, Park TK, Yang HJ, Song YB, Choi H-H, Choi S-H, Koo BK-K, Kim YJ, Chae SC, Cho MC, Kim CJ, Gwon H-C, Kim JH, Kim H-S, Jeong MH; KAMIR Investigators. Multivessel percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction with cardiogenic shock. J Am Coll Cardiol. 2018;71:845–856.
8. Bellumkonda L, Gul B, Masri SC. Evolving concepts in diagnosis and management of cardiogenic shock. Am J Cardiol. 2018;122:1104–1110.
9. Koite D, Khera S, Aronow WS, Mujib M, Palaniswamy C, Sule S, Jain D, Gottsis W, Ahmed A, Frishman WH, Fonarow GC. Trends in incidence, management,
and outcomes of cardiogenic shock complicating ST-elevation myocardial infarction in the United States. J Am Heart Assoc. 2014;3:e000590. DOI: 10.1161/JAHA.113.000590.

10. De Luca L, Oliviari Z, Farina A, Gonzini L, Lucci D, Di Chiara A, Casella G, Chiarella F, Boccanielli A, Di Pasquale G, De Servi S, Bovenzi FM, Gulizia MM, Savonitto S. Temporal trends in the epidemiology, management, and outcome of patients with cardiogenic shock complicating acute coronary syndromes: management changes in cardiogenic shock. Eur J Heart Fail. 2015;17:1124–1132.

11. Ouweezen DM, Eriksen E, Sjauw KD, von Dongen IM, Hirsch A, Packer EJS, Vis MM, Wykrzykowska JJ, Koch KT, Baan J, de Winter RJ, Pie J, Lagrand WK, de Mol BAJM, Trijsen IGP, Henrikus JPS. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol. 2017;69:278–287.

12. Mahmoud AN, Elgendy IY, Mojadidi MK, Wayangankar SA, Bavry AA, Anderson DB, Forman R, Senior R, Lahiri A, Poole-Wilson PA, Pennell DJ. The pathological basis of O-wave and non-O-wave myocardial infarction. J Am Coll Cardiol. 2004;44:554–560.

13. Lehm M, Prondzinsky R, Geppert A, Rausch F, Huber K, Dannenberg A, Buerke M, Bockel M, Bockel M. Interleukin-6, -7, -8 and -10 predict outcome in acute myocardial infarction complicated by cardiogenic shock. Clin Res Cardiol. 2012;101:375–384.

14. Mahmoud AN, Egerdy IF, Mozafari MK, Wayangankar SA, Anderson DB, Pennell DJ. The pathological basis of O-wave and non-O-wave myocardial infarction. J Am Coll Cardiol. 2004;44:554–560.

15. Mahmoud AN, Egerdy IF, Mozafari MK, Wayangankar SA, Anderson DB, Pennell DJ. The pathological basis of O-wave and non-O-wave myocardial infarction. J Am Coll Cardiol. 2004;44:554–560.

16. Mahmoud AN, Egerdy IF, Mozafari MK, Wayangankar SA, Anderson DB, Pennell DJ. The pathological basis of O-wave and non-O-wave myocardial infarction. J Am Coll Cardiol. 2004;44:554–560.

17. Mahmoud AN, Egerdy IF, Mozafari MK, Wayangankar SA, Anderson DB, Pennell DJ. The pathological basis of O-wave and non-O-wave myocardial infarction. J Am Coll Cardiol. 2004;44:554–560.

18. Mahmoud AN, Egerdy IF, Mozafari MK, Wayangankar SA, Anderson DB, Pennell DJ. The pathological basis of O-wave and non-O-wave myocardial infarction. J Am Coll Cardiol. 2004;44:554–560.

19. Mahmoud AN, Egerdy IF, Mozafari MK, Wayangankar SA, Anderson DB, Pennell DJ. The pathological basis of O-wave and non-O-wave myocardial infarction. J Am Coll Cardiol. 2004;44:554–560.

20. Mahmoud AN, Egerdy IF, Mozafari MK, Wayangankar SA, Anderson DB, Pennell DJ. The pathological basis of O-wave and non-O-wave myocardial infarction. J Am Coll Cardiol. 2004;44:554–560.

21. Mahmoud AN, Egerdy IF, Mozafari MK, Wayangankar SA, Anderson DB, Pennell DJ. The pathological basis of O-wave and non-O-wave myocardial infarction. J Am Coll Cardiol. 2004;44:554–560.

22. Mahmoud AN, Egerdy IF, Mozafari MK, Wayangankar SA, Anderson DB, Pennell DJ. The pathological basis of O-wave and non-O-wave myocardial infarction. J Am Coll Cardiol. 2004;44:554–560.

23. Mahmoud AN, Egerdy IF, Mozafari MK, Wayangankar SA, Anderson DB, Pennell DJ. The pathological basis of O-wave and non-O-wave myocardial infarction. J Am Coll Cardiol. 2004;44:554–560.

24. Mahmoud AN, Egerdy IF, Mozafari MK, Wayangankar SA, Anderson DB, Pennell DJ. The pathological basis of O-wave and non-O-wave myocardial infarction. J Am Coll Cardiol. 2004;44:554–560.

25. Mahmoud AN, Egerdy IF, Mozafari MK, Wayangankar SA, Anderson DB, Pennell DJ. The pathological basis of O-wave and non-O-wave myocardial infarction. J Am Coll Cardiol. 2004;44:554–560.

26. Mahmoud AN, Egerdy IF, Mozafari MK, Wayangankar SA, Anderson DB, Pennell DJ. The pathological basis of O-wave and non-O-wave myocardial infarction. J Am Coll Cardiol. 2004;44:554–560.

27. Mahmoud AN, Egerdy IF, Mozafari MK, Wayangankar SA, Anderson DB, Pennell DJ. The pathological basis of O-wave and non-O-wave myocardial infarction. J Am Coll Cardiol. 2004;44:554–560.
postcardiomyotomy shock: experience with the Abiomed BVS system. *J Card Surg.* 1999;14:288–293.

49. Basir MB, Schreiber TL, Grines CL, Dixon SR, Moses JW, Maini BS, Khandelwal AK, Ohman EM, O’Neill WW. Effect of early initiation of mechanical circulatory support on survival in cardiogenic shock. *Am J Cardiol.* 2017;119:845–851.

50. Wedan K, Gielen S, Ebelt H, Hochman JS. Mechanical circulatory support in cardiogenic shock. *Eur Heart J.* 2014;35:156–167.

51. Fincke R, Hochman JS, Lowe AM, Menon V, Slater JN, Webb JG, LeJemtel TH, Werdan K, Gielen S, Ebelt H, Hochman JS. Mechanical circulatory support in cardiogenic shock: the PROTECT II study. *Circulation.* 2012;126:1717–1727.

52. Fincke R, Schreiber TL, Dixon S, Alasadaw K, Patel K, Almany S, Khandelwal A, Hanson I, George A, Ashbrook M, Blank N, Abdelalalam M, Sareen N, Timmis SBH, O’Neill M. Feasibility of early mechanical circulatory support in acute myocardial infarction complicated by cardiogenic shock: the Detroit cardiogenic shock initiative. *Catheter Cardiovasc Interv.* 2018;91:454–461.

53. Ho SN, Kaisersi D, Gaba M, McCormick DJ, Goldberg S. Left ventricular assist for high-risk percutaneous coronary intervention. *J Invasive Cardiol.* 2012;24:544–550.

54. Ouweeene DM, Henriques JPS. Percutaneous cardiac support devices for cardiogenic shock: current indications and recommendations. *Heart.* 2012;98:1246–1254.

55. Thiele H, Zeymer U, Neumann F-J, Ferenc M, Olbrich H-G, Hausleiter J, de Waha AK, Ohman EM, Ebelt H, Schneider S, Wedan K, Schuler G. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. *Lancet.* 2013;382:1638–1645.

56. Patel MR, Smallding RW, Thiele H, Barnhart HX, Zhou Y, Chandra P, Cohen M, French J, Perera D, Ohman EM. Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial. *JAMA.* 2011;306:1329.

57. Kovacic JC, Kini A, Banerjee S, Dangas G, Massaro J, Mehran R, Popma J, O’Neill WW, Sharma SK. Patients with 3-vessel coronary artery disease and impaired ventricular function undergoing PCI with Impella 2.5 hemodynamic support have improved 90-day outcomes compared to intra-aortic balloon pump: a sub-study of the PROTECT II trial. *J Interv Cardiol.* 2015;28:32–40.

58. Dangas GD, Kini AS, Sharma SK, Henriques JPS, Claessens BE, Dixon SR, Massaro JM, Palacios I, Popma JJ, Ohman M, Stone GW, O’Neill WW. Impact of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump on prognostically important clinical outcomes in patients undergoing high-risk percutaneous coronary intervention (from the PROTECT II randomized trial). *Am J Cardiol.* 2014;113:222–228.

59. Manzo-Silberman S, Fichet J, Mathonnet A, Varenne O, Ricome S, Chaib A, Zuber B, Spaulding C, Cariou A. Percutaneous left ventricular assist device support for post cardiac arrest shock: comparison of intra aortic blood pump and IMPELLA Recover LP2.5. *Resuscitation.* 2013;84:609–615.

60. Paden ML, Conrad SA, Rycus PT, Thiaagarajan RR; ELSO Registry. Extracorporeal life support organization registry report 2012. *ASAO J.* 2013;59:202–210.

61. Wong SC, Sanborn T, Sleeper LA, Webb JG, Pilchik R, Hart D, Mejnantwicz S, Antonelli TA, Lange R, French JK, Bergman G, Lejentel T, Hochman JS. Angiographic findings and clinical correlates in patients with cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. Should we emergently revascularize Occluded Coronaries for cardiogenic shock? *J Am Coll Cardiol.* 2000;36:1077–1083.

62. Rogers PA, Daye J, Huang H, Bluestein A, Virani S, Alam M, Paniagua D, Kar B, Bozkurt B, Ballantyne CM, Deswal A, Jneid H. Revascularization improves mortality in elderly patients with acute myocardial infarction complicated by cardiogenic shock. *Int J Cardiol.* 2014;172:239–241.

63. Thiele H, Akin I, Sandri M, Fuerneau G, de Waha S, Meyer-Sarai R, Nordbeck P, Geisler T, Landmesser U, Skunk C, Fach A, Lapp H, Piek JJ, Not M, Goslar T, Felix SB, Maier LS, Stepinska J, Oldroyd K, Serytys P, Montalescot G, Barthelemy O, Huber K, Windecker S, Savonitto S, Torremante P, Vrints C, Schneider S, Desch S, Zeymer U, CULPRIT-SHOCK Investigators. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. *N Engl J Med.* 2017;377:2419–2432.

64. Engstrøm T, Kelbaek H, Helqvist S, Hafsten DE, Klavgaard L, Holmvang L, Jørgensen E, Pedersen F, Saunamäki K, Clemenpsen M, De Backer O, Rauld D, Jilved H-H, Viladres AB, Aarae J, Jensen SE, Raugaard B, Keber L; DANAMI-3—PRIMULTI Investigators. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. *Lancet.* 2015;386:665–70.

65. Webb JG, Kleiman NS, Webb JG, Neill WW, Neill Md WW. Feasibility of early mechanical circulatory support in cardiogenic shock complicating acute myocardial infarction: the PROTECT II study. *J Am Coll Cardiol.* 2012;60:1727–1735.

66. Thiele H, Akin I, Sandri M, Fuerneau G, de Waha S, Meyer-Sarai R, Nordbeck P, Geisler T, Landmesser U, Skunk C, Fach A, Lapp H, Piek JJ, Not M, Goslar T, Felix SB, Maier LS, Stepinska J, Oldroyd K, Serytys P, Montalescot G, Barthelemy O, Huber K, Windecker S, Savonitto S, Torremante P, Vrints C, Schneider S, Desch S, Zeymer U, CULPRIT-SHOCK Investigators. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. *N Engl J Med.* 2017;377:2419–2432.

67. Wald DS, Morris JK, Wald NJ, Chase AJ, Edwards RJ, Hughes LO, Berry C, Jørgensen E, Saunamäki K, Clemenpsen M, De Backer O, Rauld D, Jilved H-H, Viladres AB, Aarae J, Jensen SE, Raugaard B, Keber L; DANAMI-3—PRIMULTI Investigators. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. *Lancet.* 2015;386:665–70.

68. Kang J, Aziz G, Saha T, Naqui SY, Goldberg S. Hybrid revascularization: a review. *Cardiology.* 2014;140:35–44.

**Key Words:** acute coronary syndrome • cardiogenic shock • revascularization • shock